FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136278741> ?p ?o ?g. }

• W3136278741 abstract "Introduction: Progressive myoclonic epilepsies (PMEs) are a heterogenous group of genetic diseases presenting with epilepsy, cognitive impairment, and severe action myoclonus, which can severely affect daily life activities and independent walking ability. Perampanel is a recent commercially available antiseizure medication with high efficacy against generalized seizures. Some reports supported the role of perampanel in ameliorating action myoclonus in PMEs. Here, we aimed to describe a case series and provide a systematic literature review on perampanel effects on PMEs. Methods: We report the perampanel effectiveness on myoclonus, daily life activities, and seizures on an original Italian multicenter case series of 11 individuals with PMEs. Then, using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, we performed a systematic review on perampanel effect on myoclonus and disability in PMEs. We searched PubMed, Scopus, and Google Scholar articles on perampanel and PMEs up to June 2020. No prospective trials were found. We reviewed 11 case series manuscripts reporting 104 cases of different PMEs. Results: Here, we are reporting the effectiveness of perampanel in five individuals affected by Unverricht–Lundborg disease, three by Lafora disease, two by sialidosis, and one by an undetermined PME. Nine out of 11 individuals improved their disability related to the action myoclonus (two with Lafora disease did not). Among the 104 persons with PMEs collected by the systematic review, we found that more than half of the patients receiving perampanel exhibited an amelioration of action myoclonus and, consequently, of their independence in daily life activities. The Unverricht–Lundborg disease seemed to show the best clinical response to perampanel, in comparison with the other more severe PMEs. A significant seizure reduction was achieved by almost all persons with active epilepsy. Only 11% of PME patients dropped out due to inefficacy. Conclusions: Perampanel demonstrated a beneficial effect with regard to action myoclonus, disability, and seizures and was well-tolerated in people with PMEs, independently from their genetic diagnosis. Given the limited scientific evidence, broader prospective trials should be encouraged." @default.
• W3136278741 created "2021-03-29" @default.
• W3136278741 creator A5000317662 @default.
• W3136278741 creator A5007334506 @default.
• W3136278741 creator A5028808285 @default.
• W3136278741 creator A5033179657 @default.
• W3136278741 creator A5034666135 @default.
• W3136278741 creator A5041865645 @default.
• W3136278741 creator A5044341102 @default.
• W3136278741 creator A5050259375 @default.
• W3136278741 creator A5061382434 @default.
• W3136278741 creator A5061590058 @default.
• W3136278741 creator A5076959356 @default.
• W3136278741 creator A5079655995 @default.
• W3136278741 date "2021-03-24" @default.
• W3136278741 modified "2023-09-29" @default.
• W3136278741 title "Perampanel Improves Cortical Myoclonus and Disability in Progressive Myoclonic Epilepsies: A Case Series and a Systematic Review of the Literature" @default.
• W3136278741 cites W1512594967 @default.
• W3136278741 cites W1862220344 @default.
• W3136278741 cites W1982229026 @default.
• W3136278741 cites W2034316298 @default.
• W3136278741 cites W2060581505 @default.
• W3136278741 cites W2080669639 @default.
• W3136278741 cites W2134412359 @default.
• W3136278741 cites W2140620980 @default.
• W3136278741 cites W2293385269 @default.
• W3136278741 cites W2479317925 @default.
• W3136278741 cites W2529239017 @default.
• W3136278741 cites W2529787665 @default.
• W3136278741 cites W2556192593 @default.
• W3136278741 cites W2576440140 @default.
• W3136278741 cites W2586560085 @default.
• W3136278741 cites W2616890027 @default.
• W3136278741 cites W2791702085 @default.
• W3136278741 cites W2894436064 @default.
• W3136278741 cites W2914471022 @default.
• W3136278741 cites W2945237735 @default.
• W3136278741 cites W2963870685 @default.
• W3136278741 cites W2969004530 @default.
• W3136278741 cites W2969944708 @default.
• W3136278741 cites W2990512104 @default.
• W3136278741 cites W3027011406 @default.
• W3136278741 cites W3034831461 @default.
• W3136278741 cites W3034923348 @default.
• W3136278741 cites W3046537805 @default.
• W3136278741 cites W3132897759 @default.
• W3136278741 doi "https://doi.org/10.3389/fneur.2021.630366" @default.
• W3136278741 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8024635" @default.
• W3136278741 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33841303" @default.
• W3136278741 hasPublicationYear "2021" @default.
• W3136278741 type Work @default.
• W3136278741 sameAs 3136278741 @default.
• W3136278741 citedByCount "12" @default.
• W3136278741 countsByYear W31362787412021 @default.
• W3136278741 countsByYear W31362787412022 @default.
• W3136278741 countsByYear W31362787412023 @default.
• W3136278741 crossrefType "journal-article" @default.
• W3136278741 hasAuthorship W3136278741A5000317662 @default.
• W3136278741 hasAuthorship W3136278741A5007334506 @default.
• W3136278741 hasAuthorship W3136278741A5028808285 @default.
• W3136278741 hasAuthorship W3136278741A5033179657 @default.
• W3136278741 hasAuthorship W3136278741A5034666135 @default.
• W3136278741 hasAuthorship W3136278741A5041865645 @default.
• W3136278741 hasAuthorship W3136278741A5044341102 @default.
• W3136278741 hasAuthorship W3136278741A5050259375 @default.
• W3136278741 hasAuthorship W3136278741A5061382434 @default.
• W3136278741 hasAuthorship W3136278741A5061590058 @default.
• W3136278741 hasAuthorship W3136278741A5076959356 @default.
• W3136278741 hasAuthorship W3136278741A5079655995 @default.
• W3136278741 hasBestOaLocation W31362787411 @default.
• W3136278741 hasConcept C118552586 @default.
• W3136278741 hasConcept C15744967 @default.
• W3136278741 hasConcept C17744445 @default.
• W3136278741 hasConcept C187212893 @default.
• W3136278741 hasConcept C189708586 @default.
• W3136278741 hasConcept C199539241 @default.
• W3136278741 hasConcept C2776538686 @default.
• W3136278741 hasConcept C2778186239 @default.
• W3136278741 hasConcept C2779473830 @default.
• W3136278741 hasConcept C2780836401 @default.
• W3136278741 hasConcept C2781467325 @default.
• W3136278741 hasConcept C71924100 @default.
• W3136278741 hasConceptScore W3136278741C118552586 @default.
• W3136278741 hasConceptScore W3136278741C15744967 @default.
• W3136278741 hasConceptScore W3136278741C17744445 @default.
• W3136278741 hasConceptScore W3136278741C187212893 @default.
• W3136278741 hasConceptScore W3136278741C189708586 @default.
• W3136278741 hasConceptScore W3136278741C199539241 @default.
• W3136278741 hasConceptScore W3136278741C2776538686 @default.
• W3136278741 hasConceptScore W3136278741C2778186239 @default.
• W3136278741 hasConceptScore W3136278741C2779473830 @default.
• W3136278741 hasConceptScore W3136278741C2780836401 @default.
• W3136278741 hasConceptScore W3136278741C2781467325 @default.
• W3136278741 hasConceptScore W3136278741C71924100 @default.
• W3136278741 hasLocation W31362787411 @default.
• W3136278741 hasLocation W31362787412 @default.
• W3136278741 hasLocation W31362787413 @default.
• W3136278741 hasOpenAccess W3136278741 @default.
• W3136278741 hasPrimaryLocation W31362787411 @default.
• W3136278741 hasRelatedWork W2033882290 @default.

• next